{{scheme.chgp}}%
{{scheme.chgp}}%
No Matches Found
{{scheme.chgp}}%
No Matches Found
No Matches Found
Archit Organosys Ltd Upgraded to Sell on Technical Improvements Despite Lingering Fundamental Concerns
Archit Organosys Ltd has seen its investment rating upgraded from Strong Sell to Sell as of 1 January 2026, driven primarily by improvements in its technical indicators. While the company continues to face challenges in long-term fundamentals and valuation metrics, recent positive financial results and a shift in technical trends have prompted a reassessment of its market stance.
Archit Organosys Ltd is Rated Strong Sell
Archit Organosys Ltd is rated Strong Sell by MarketsMOJO, with this rating last updated on 23 December 2025. However, the analysis and financial metrics discussed here reflect the stock's current position as of 25 December 2025, providing investors with the most up-to-date view of the company’s fundamentals, returns, and market performance.
Archit Organosys Forms Death Cross, Signalling Potential Bearish Trend
Archit Organosys, a micro-cap player in the Commodity Chemicals sector, has recently formed a Death Cross, a technical pattern where the 50-day moving average crosses below the 200-day moving average. This development often signals a shift towards a bearish trend and suggests a weakening momentum in the stock’s price trajectory over the longer term.
Archit Organosys Sees Revision in Market Evaluation Amidst Challenging Commodity Chemicals Sector
Archit Organosys, a microcap player in the commodity chemicals sector, has undergone a revision in its market evaluation reflecting shifts in its fundamental and technical outlook. This adjustment follows a period marked by subdued returns and a cautious market stance, underscoring the complexities faced by smaller companies in this segment.
Why is Archit Organosys falling/rising?
On 28 Nov, Archit Organosys Ltd recorded a 1.96% rise in its share price, closing at ₹41.72, marking a continuation of a short-term recovery despite a longer-term trend of underperformance relative to the broader market benchmarks.
Archit Organosys Q2 FY26: Profitability Under Pressure as Margins Collapse
Archit Organosys Ltd., a micro-cap commodity chemicals manufacturer, is navigating turbulent waters as its latest quarterly results reveal a sharp deterioration in operational efficiency. The company, with a market capitalisation of ₹92.00 crores, faces mounting challenges despite reporting improved topline growth in recent quarters.
Is Archit Organosys overvalued or undervalued?
As of November 13, 2025, Archit Organosys is considered overvalued with a PE ratio of 147.70, significantly higher than its peers, and has underperformed the Sensex with a year-to-date return of -6.00%.
How has been the historical performance of Archit Organosys?
Archit Organosys has experienced a declining trend in net sales and profits, with net sales dropping from 137.90 Cr in March 2022 to 113.19 Cr in March 2024, and profit after tax decreasing from 11.35 Cr to 3.28 Cr in the same period. Key financial metrics indicate a challenging performance, highlighted by a significant reduction in operating profit margin and earnings per share.
Why is Archit Organosys falling/rising?
As of 11-Nov, Archit Organosys Ltd's stock price is at 45.48, showing a slight increase after two days of decline, but it has underperformed against the Sensex over the past week, month, and year. Despite trading above some moving averages, the stock's overall performance remains negative, indicating challenges in the current market context.
When is the next results date for Archit Organosys?
The next results date for Archit Organosys is 13 November 2025.
How has been the historical performance of Archit Organosys?
Archit Organosys has experienced a consistent decline in net sales and profits from March 2022 to March 2024, with net sales dropping from 137.90 Cr to 113.19 Cr and profit after tax decreasing from 11.35 Cr to 3.28 Cr. The operating profit margin also fell significantly, indicating challenging financial performance.
Is Archit Organosys overvalued or undervalued?
As of October 30, 2025, Archit Organosys is considered overvalued with a high PE ratio of 150.72 and poor alignment with earnings growth potential, despite being rated attractive compared to peers like Godrej Industries and Solar Industries.
Is Archit Organosys overvalued or undervalued?
As of October 29, 2025, Archit Organosys is fairly valued with a PE ratio of 153.25 and an EV to EBITDA of 18.74, despite recent underperformance compared to the Sensex, but it has shown strong long-term growth with a 5-year return of 175.21%.
How has been the historical performance of Archit Organosys?
Archit Organosys has experienced a decline in net sales and profits, with net sales dropping from 137.90 Cr in March 2022 to 113.19 Cr in March 2024, and profit after tax decreasing from 11.35 Cr to 3.28 Cr in the same period. The earnings per share also fell from 5.53 to 1.6, indicating a challenging financial environment.
How has been the historical performance of Archit Organosys?
Archit Organosys has experienced a decline in net sales and profits from March 2022 to March 2024, with net sales dropping from 137.90 Cr to 113.19 Cr and profit after tax decreasing from 11.35 Cr to 3.28 Cr during this period. Overall, the company's financial metrics indicate a challenging trend with reduced revenues and earnings.
Is Archit Organosys overvalued or undervalued?
As of October 17, 2025, Archit Organosys is considered overvalued with a high PE ratio of 154.30 and an EV to EBIT of 107.77, despite its attractive valuation grade, as it has underperformed compared to peers and the Sensex over the past three years.
Is Archit Organosys overvalued or undervalued?
As of October 17, 2025, Archit Organosys is considered undervalued with an attractive valuation grade, highlighted by a PE ratio of 154.30 and strong growth potential, despite recent stock performance lagging behind the Sensex.
Is Archit Organosys overvalued or undervalued?
As of October 17, 2025, Archit Organosys is considered undervalued with an attractive valuation grade, highlighted by a low PEG ratio of 0.02 and a high PE ratio of 154.30, indicating strong growth potential despite recent stock performance lagging behind the Sensex.
How has been the historical performance of Archit Organosys?
Archit Organosys has shown a declining trend in financial performance, with net sales dropping from 137.90 Cr in March 2022 to 113.19 Cr in March 2024, and profit after tax decreasing from 11.35 Cr to 3.28 Cr over the same period. Key metrics such as operating profit and earnings per share have also significantly declined.
{{list.post_title}}
{{list.post_excerpt}}
{{list.post_title}}
{{list.post_excerpt}}
